Regeneron Pharmaceuticals Inc REGN:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD

After Hours: Last | 5:54 PM EST

461.00

-0.57 (-0.12%)

Volume

93,029

461.57

+12.19 (+2.71%)

Volume

1,120,099

52 week range

418.01 - 664.64

...

Loading . . .

KEY STATS

Open451.58
Day High463.83
Day Low449.30
Prev Close449.38
52 Week High664.64
52 Week High Date07/20/20
52 Week Low418.01
52 Week Low Date03/13/20
Market Cap49.448B
Shares Out107.13M
10 Day Average Volume1.12M
Dividend-
Dividend Yield-
Beta0.18
1 Year % Change-5.45

RATIOS/PROFITABILITY

EPS (TTM)30.69
P/E (TTM)15.04
Fwd P/E (NTM)10.92
EBITDA (MRQ)3.812B
ROE (MRQ)31.77%
Revenue (MRQ)8.497B
Gross Margin (MRQ)86.82%
Net Margin (MRQ)41.35%
Debt To Equity (MRQ)24.45%

EVENTS

Earnings Date05/03/2021
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest Regeneron Pharmaceuticals Inc News

March 2, 2021

Cathie Wood is happy about tech's ‘reality check’ as she adds to core plays CNBC.com

February 25, 2021

$100 billion market cap is the blue-sky scenario for Moderna, analyst says CNBC.com

February 16, 2021

These stocks will drive the next leg of the rally, says BMO CNBC.com

February 13, 2021

A review of what Cathie Wood's Ark Invest bought and sold this week CNBC.com

February 11, 2021

Roche arthritis drug reduces death in severe Covid patients, researchers say CNBC.com

Latest REGN News From Our Partners

March 4, 2021

FDA accepts Regeneron, Sanofi's Dupixent application for children with asthma Seeking Alpha

March 3, 2021

Regeneron and Kiniksa sign commercial supply agreement for Rilonacept Seeking Alpha

March 2, 2021

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Cowen 41st Annual Health Care Conference (Transcript) Seeking Alpha

March 1, 2021

Green's Portfolio - February 2021 Seeking Alpha

February 27, 2021

Regeneron’s antibody cocktail shows promise in cat-allergic patients with mild asthma Seeking Alpha

QUOTE FINDER

Market Movers

Profile

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases....

P. Roy Vagelos M.D.

Chairman

Leonard Schleifer M.D., Ph.D.

President

George Yancopoulos M.D., Ph.D.

Co-President

Robert Landry

Chief Financial Officer

Daniel Van Plew

Executive Vice President

Christopher Fenimore

Vice President

Address

777 Old Saw Mill River Rd

Tarrytown, NY

10591-6717

United States

https://www.regeneron.com/